Zhitong Finance App News, Cornerstone Pharmaceutical-B (02616) announced that the company has reached a cooperation with Kimia Therapeutics, Inc. (“Kimia”), a biopharmaceutical company focusing on the development of innovative oncology and immunology drugs. The two sides will jointly advance the clinical development of a solid tumor drug candidate with similar pioneering potential and targeting the DNA damage response (DDR) pathway critical to solid tumor survival. Cornerstone Pharmaceuticals will lead the clinical development of this candidate in mainland China and Australia.

This cooperation further confirms the industry's international recognition of Cornerstone Pharmaceuticals' mature clinical development and drug registration capabilities, and is also in line with the company's strategy to carefully promote external innovation and global layout. At the same time, Cornerstone Pharmaceuticals will share the global commercialization value of this first-of-its-kind drug through milestone payments and sales sharing.

Kimia is headquartered in Berkeley, California, and relies on its self-developed integrated ATLAS platform to enable drug discovery and development of small molecule drugs with AI. Kimia is a portfolio company of The Column Group (TCG), a well-known life sciences investment institution. TCG focuses on incubating and investing in biotechnology companies, covering the entire development cycle from early scientific innovation and clinical development to strategic transactions.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.